References
- Plunkett W., Gandhi V., Huang P., et al. Fludara-bine: Pharmacokinetics, mechanisms of action and rationale for combination therapies. Semin. Oncol. 1993; 20(Suppl. 7)2–12
- Leiby J.M., Snider K.M., Kraut E.H., Metz E.N., Malspeis L., Grever M.R. Phase II trial of 9-β-D-Arabinofuranosyl-2-fluroadenine 5′-Monophosphate in non-hodgkin's lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res. 1987; 47: 2719–2722
- Keating M.J., Kantarjian H., Talpaz M., et al. Flu-darabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
- Hochster H., Cassileth P. Fludarabine phosphate therapy of non-hodgkin's lymphoma. Semin. Oncol. 1990; 17(Suppl. 8)63–85
- Keating M.J. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 1990; 17(Suppl. 8)49–62
- Hochster H.S., Kim K., Green M.D., et al. Activity of fludarabine in previously treated non-hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Study Group. J. Clin. Oncol. 1992; 10: 28–32
- Redman J.R., Cabanillas E., Velasquez W.S., et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J. Clin. Oncol. 1992; 10: 790–794
- Zinzani P.L., Lauria F., Rondelli D., et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur. J. Haematol. 1993; 51: 93–97
- Pigaditou A., Rohatiner A. Z. S., Whelan J.S., et al. Fludarabine in low-grade lymphoma. Semin. Oncol. 1993; 20(Suppl. 7)24–27
- Anaissie E., Kontoyiannis D.P., Kantarjian H., Elting L., Robertson L.E., Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann. Intern. Med. 1992; 117: 466–469
- Keating M.J., O'Brien S., Kantarjian H., et al. Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leukemia and Lymphoma 1993; 10(Suppl.)139–145
- Keating M.J., Kantarjian H., O'Brien S., et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
- Robertson L.E., Huh Y.O., Butler J.J., et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic and molecular analysis. Blood 1992; 80: 29–36
- Keating M.J., O'Brien S., Kantarjian H., et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878–2884
- O'Brien S., Kantarjian H., Beran M., et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700
- Cohen R.B., Abdallah J.M., Gray J.R., Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann. Intern. Med. 1993; 118: 114–116